ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1481

Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
Abstract Number: 2432

Duffy Null Genotype and Autoantibodies Synergistically Contribute to Severe Leukopenia in Systemic Lupus Erythematosus
Abstract Number: 0144

Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
Abstract Number: 2577

Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
Abstract Number: 1697

Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
Abstract Number: 0887

Dynamics of cytotoxic and regulatory CD8 T cells underlies outcome in ICI-myotoxicity
Abstract Number: 0115

Dysfunctional Mitophagy Propels Neutrophil Hyperactivity and Thrombosis in Antiphospholipid Syndrome
Abstract Number: 1711

Dysfunctional Neurobiology Of The Insula Characterizes Fatigue In Psoriatic Arthritis
Abstract Number: 0908

E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Abstract Number: 0488

Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Abstract Number: 2336

Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry
Abstract Number: 2625

Early Detection of Knee Osteoarthritis – The Role of a Composite Disease Activity Metric: Data from the Osteoarthritis Initiative
Abstract Number: 1610

Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
Abstract Number: 2324

Early Prediction of Complex Forms of Spondyloarthritis Using Artificial Intelligence: A Modeling Study Based on Routine Clinical Data
Abstract Number: 2234

Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].